CDK6 inhibitor

DRUG CLASS:

CDK6 inhibitor

News alerts, weekly reports and conference planners

Related drugs:

BAP1 mutation + IDH2 R172W + CDKN2A deletion + CDKN2B deletion	Cholangiocarcinoma	BAP1 mutation + IDH2 R172W + CDKN2A deletion + CDKN2B deletion	Cholangiocarcinoma	palbociclib Sensitive: C4 – Case Studies Onco Targets Ther - 2 weeks (New C4) palbociclib Sensitive : C4 Onco Targets Ther - 2wk	palbociclib Sensitive: C4 – Case Studies Onco Targets Ther - 2 weeks palbociclib Sensitive : C4 Onco Targets Ther - 2 weeks - (New C4)
PIK3CA mutation	Colorectal Cancer	PIK3CA mutation	Colorectal Cancer	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2wk	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2wk	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
PIK3CA mutation + KRAS mutation	Colorectal Cancer	PIK3CA mutation + KRAS mutation	Colorectal Cancer	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2wk	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
PIK3CA wild-type + KRAS wild-type	Colorectal Cancer	PIK3CA wild-type + KRAS wild-type	Colorectal Cancer	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks (New D) alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2wk	alpelisib + ribociclib Sensitive: D – Preclinical ASCO-GI 2023 - 2 weeks alpelisib + ribociclib Sensitive : D ASCO-GI 2023 - 2 weeks - (New D)
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	palbociclib Sensitive: A1 - Approval palbociclib Sensitive : A1	palbociclib Sensitive: A1 - Approval palbociclib Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	ribociclib Sensitive: A1 - Approval ribociclib Sensitive : A1	ribociclib Sensitive: A1 - Approval ribociclib Sensitive : A1
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	abemaciclib Sensitive: A1 - Approval abemaciclib Sensitive : A1	abemaciclib Sensitive: A1 - Approval abemaciclib Sensitive : A1
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	ribociclib Sensitive: A1 - Approval ribociclib Sensitive : A1	ribociclib Sensitive: A1 - Approval ribociclib Sensitive : A1
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	trastuzumab + abemaciclib Sensitive: A2 - Guideline trastuzumab + abemaciclib Sensitive : A2	trastuzumab + abemaciclib Sensitive: A2 - Guideline trastuzumab + abemaciclib Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	ribociclib Sensitive: A2 - Guideline ribociclib Sensitive : A2	ribociclib Sensitive: A2 - Guideline ribociclib Sensitive : A2
No biomarker	Breast Cancer	No biomarker	Breast Cancer	abemaciclib Sensitive: A2 - Guideline abemaciclib Sensitive : A2	abemaciclib Sensitive: A2 - Guideline abemaciclib Sensitive : A2
No biomarker	Liposarcoma	No biomarker	Liposarcoma	palbociclib Sensitive: A2 - Guideline palbociclib Sensitive : A2	palbociclib Sensitive: A2 - Guideline palbociclib Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	palbociclib Sensitive: A2 - Guideline palbociclib Sensitive : A2	palbociclib Sensitive: A2 - Guideline palbociclib Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	abemaciclib Sensitive: A2 - Guideline abemaciclib Sensitive : A2	abemaciclib Sensitive: A2 - Guideline abemaciclib Sensitive : A2
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	palbociclib Resistant: A2 - Guideline palbociclib Resistant : A2	palbociclib Resistant: A2 - Guideline palbociclib Resistant : A2
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	Aromatase inhibitor + palbociclib Sensitive: A2 - Guideline Aromatase inhibitor + palbociclib Sensitive : A2	Aromatase inhibitor + palbociclib Sensitive: A2 - Guideline Aromatase inhibitor + palbociclib Sensitive : A2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	CDK6 inhibitor Sensitive: A2 - Guideline CDK6 inhibitor Sensitive : A2	CDK6 inhibitor Sensitive: A2 - Guideline CDK6 inhibitor Sensitive : A2
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	CDK6 inhibitor + Aromatase inhibitor Sensitive: A2 - Guideline CDK6 inhibitor + Aromatase inhibitor Sensitive : A2	CDK6 inhibitor + Aromatase inhibitor Sensitive: A2 - Guideline CDK6 inhibitor + Aromatase inhibitor Sensitive : A2
PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	PIK3CA mutation + HR positive	HER2 Negative Breast Cancer	CDK6 inhibitor + alpelisib Sensitive: A2 - Guideline CDK6 inhibitor + alpelisib Sensitive : A2	CDK6 inhibitor + alpelisib Sensitive: A2 - Guideline CDK6 inhibitor + alpelisib Sensitive : A2
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	trilaciclib Sensitive: B - Late Trials trilaciclib Sensitive : B	trilaciclib Sensitive: B - Late Trials trilaciclib Sensitive : B
CCNE1 overexpression	Hormone Receptor Positive Breast Cancer	CCNE1 overexpression	Hormone Receptor Positive Breast Cancer	palbociclib Resistant: B - Late Trials palbociclib Resistant : B	palbociclib Resistant: B - Late Trials palbociclib Resistant : B
ER mutation	Estrogen Receptor Positive Breast Cancer	ER mutation	Estrogen Receptor Positive Breast Cancer	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B
ER mutation	Breast Cancer	ER mutation	Breast Cancer	palbociclib Resistant: B - Late Trials palbociclib Resistant : B	palbociclib Resistant: B - Late Trials palbociclib Resistant : B
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B	palbociclib Sensitive: B - Late Trials palbociclib Sensitive : B
PLK1-H	Hormone Receptor Positive Breast Cancer	PLK1-H	Hormone Receptor Positive Breast Cancer	palbociclib Resistant: B - Late Trials palbociclib Resistant : B	palbociclib Resistant: B - Late Trials palbociclib Resistant : B
ER positive + PGR negative + HER-2 negative	HER2 Negative Breast Cancer	ER positive + PGR negative + HER-2 negative	HER2 Negative Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B
KRAS G13C	Non Small Cell Lung Cancer	KRAS G13C	Non Small Cell Lung Cancer	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	CDK6 inhibitor Sensitive: B - Late Trials CDK6 inhibitor Sensitive : B	CDK6 inhibitor Sensitive: B - Late Trials CDK6 inhibitor Sensitive : B
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B	abemaciclib Sensitive: B - Late Trials abemaciclib Sensitive : B
HR positive	Hormone Receptor Positive Breast Cancer	HR positive	Hormone Receptor Positive Breast Cancer	palbociclib + abemaciclib Sensitive: B - Late Trials palbociclib + abemaciclib Sensitive : B	palbociclib + abemaciclib Sensitive: B - Late Trials palbociclib + abemaciclib Sensitive : B
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
HER-2 mutation	Breast Cancer	HER-2 mutation	Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
AKT1 mutation	Breast Cancer	AKT1 mutation	Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
BRCA1 mutation	Breast Cancer	BRCA1 mutation	Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B
BRCA2 mutation	Breast Cancer	BRCA2 mutation	Breast Cancer	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B	ribociclib Sensitive: B - Late Trials ribociclib Sensitive : B

CDK6 inhibitor

CDK6 inhibitor

Associations(371)

Associations
(371)